Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776656 | 0.94 | SLC6A4 (0.32) | SLC6A4SLC6A3 | |
| SCHEMBL23075246 | 0.82 | — | — | |
| SCHEMBL5868545 | 0.82 | SLC6A4 (0.35) | SLC6A4SLC6A3 | |
| SCHEMBL20043478 | 0.77 | — | — | |
| SCHEMBL22926741 | 0.77 | — | — | |
| SCHEMBL10089210 | 0.74 | SLC6A4 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL4337964 | 0.74 | SLC6A4 (0.33) | SLC6A4SLC6A3 | |
| SCHEMBL20976642 | 0.74 | ALDH1A1 (0.32) | — | |
| SCHEMBL2015326 | 0.71 | — | — | |
| SCHEMBL128026 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174877-B1 | INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-20170079965-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-9546166-B2 | Indolizine derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2017-01-17 | — | — | US | disclosed |
| US-20160031879-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| WO-2016019228-A1 | INDOLIZINE DERIVATIVES WHICH ARE APPLICABLE TO NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170079965-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX5, P2RX4, P2RX3 | SLC6A4 108/4885SLC6A3 171/4885 |
| US-20160031879-A1 | NOVEL INDOLIZINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX5, P2RX4, P2RX3 | SLC6A4 108/4885SLC6A3 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.